English
lucius luciregor regorafenib tablets 40mg
Indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and—if KRAS wild-type—anti-EGFR therapy.
Description
Add to cart
Product Description
Product Name: LuciRegor
Chinese Name: Regorafenib Tablets
English Name: Regorafenib Tablets
【Indications】
LuciRegor is a kinase inhibitor indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and anti-VEGF therapy, and—in cases of KRAS wild-type status—anti-EGFR therapy.
【Dosage and Administration】
Recommended dosage: 160 mg orally once daily for the first 21 days of each 28-day cycle.
Take LuciRegor with food (a low-fat breakfast).
【Strength】 40 mg/tablet, 28 tablets/box.
【Contraindications】 None.
【Warnings and Precautions】
Hemorrhage: Permanently discontinue LuciRegor in cases of severe or life-threatening hemorrhage.
Dermatologic toxicity: Interrupt, reduce the dose, or discontinue LuciRegor based on the severity and duration of dermatologic toxicity.
Hypertension: Temporarily or permanently discontinue LuciRegor for severe or uncontrolled hypertension.
Cardiac ischemia and infarction: Withhold LuciRegor for new or acute cardiac ischemia/infarction; resume only after the acute ischemic event has resolved.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue LuciRegor.
Gastrointestinal perforation or fistula: Discontinue LuciRegor.
Wound healing complications: Stop LuciRegor prior to surgery. Discontinue in patients with wound dehiscence.
Embryo-fetal toxicity: May cause fetal harm. Advise females of the potential risk to the fetus.
【Adverse Reactions】
The most common adverse reactions (≥30%) are asthenia/fatigue, decreased appetite and food intake, hand-foot skin reaction (HFSR) [palmar-plantar erythrodysesthesia (PPE)], diarrhea, mucositis, weight loss, infection, hypertension, and dysphonia. [Drug Interactions]
Potent CYP3A4 inducers: Avoid the use of potent CYP3A4 inducers.
[Use in Specific Populations]
Lactation: Weigh the benefits and risks of the drug to the mother and the nursing infant to decide whether to discontinue the drug or discontinue breastfeeding.
[Storage]
Store at 20°C to 25°C (68°F to 77°F); brief excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture.
